Literature DB >> 18774583

Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model.

Jennifer L Kyle1, Scott J Balsitis, Luhua Zhang, P Robert Beatty, Eva Harris.   

Abstract

The four serotypes of dengue virus (DENV1-4) are causative agents of dengue fever and dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Previous DENV infection is a risk factor for DHF/DSS during subsequent infection by a different serotype. Nonetheless, most primary and secondary DENV infections are asymptomatic. To investigate the possible mechanisms of immune protection in vivo, 129/Pas mice lacking IFN-alpha/beta and -gamma receptors (AG129) were used to model secondary infection using both DENV1-DENV2 and DENV2-DENV4 sequences. At intervals between sequential infections of 4 to 52 weeks, protection against secondary heterologous DENV infection was observed. Passive transfer of DENV-immune serum was protective against replication of heterologous challenge virus in all tissues tested, whereas adoptive transfer of DENV-immune cells significantly protected mice from replication of the challenge virus only when a lower inoculum was administered. These findings are relevant for understanding both natural and vaccine-induced immunity to DENV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774583      PMCID: PMC2590773          DOI: 10.1016/j.virol.2008.08.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

1.  Long-term memory cellular immune response to dengue virus after a natural primary infection.

Authors:  Beatríz Sierra; Gissel García; Ana B Pérez; Luis Morier; Rayner Rodríguez; Mayling Alvarez; María G Guzmán
Journal:  Int J Infect Dis       Date:  2002-06       Impact factor: 3.623

2.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 3.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

4.  Development of a novel mouse model for dengue virus infection.

Authors:  J An; J Kimura-Kuroda; Y Hirabayashi; K Yasui
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

5.  Manifestation of thrombocytopenia in dengue-2-virus-infected mice.

Authors:  Kao-Jean Huang; Shu-Yi J Li; Shiour-Ching Chen; Hsiao-Sheng Liu; Yee-Shin Lin; Trai-Ming Yeh; Ching-Chuan Liu; Huan-Yao Lei
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

6.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.

Authors:  Joseph E Blaney; Daniel H Johnson; Gracielle G Manipon; Cai-Yen Firestone; Christopher T Hanson; Brian R Murphy; Stephen S Whitehead
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

7.  Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever.

Authors:  Tadeusz J Kochel; Douglas M Watts; Scott B Halstead; Curtis G Hayes; Angelica Espinoza; Vidal Felices; Roxana Caceda; Christian T Bautista; Ysabel Montoya; Susan Douglas; Kevin L Russell
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

8.  Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand.

Authors:  Timothy P Endy; Supamit Chunsuttiwat; Ananda Nisalak; Daniel H Libraty; Sharone Green; Alan L Rothman; David W Vaughn; Francis A Ennis
Journal:  Am J Epidemiol       Date:  2002-07-01       Impact factor: 4.897

9.  Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical.

Authors:  Sujan Shresta; Jennifer L Kyle; Heidi M Snider; Manasa Basavapatna; P Robert Beatty; Eva Harris
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice.

Authors:  Sujan Shresta; Jennifer L Kyle; P Robert Beatty; Eva Harris
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  40 in total

1.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

2.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

Review 3.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

5.  Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques.

Authors:  Katherine M Mladinich; Shari M Piaskowski; Richard Rudersdorf; Christopher M Eernisse; Kim L Weisgrau; Mauricio A Martins; Jessica R Furlott; Charalambos D Partidos; Joseph N Brewoo; Jorge E Osorio; Nancy A Wilson; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2011-09-01       Impact factor: 2.846

Review 6.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

Review 7.  Mouse models of dengue virus infection for vaccine testing.

Authors:  Vanessa V Sarathy; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

8.  Virus antibody dynamics in primary and secondary dengue infections.

Authors:  Tanvi P Gujarati; G Ambika
Journal:  J Math Biol       Date:  2014-01-04       Impact factor: 2.259

9.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.